Group B streptococcus Full Value of Vaccine Assessment
Group B streptococcus (GBS) is an important cause of disease burden in every region worldwide, contributing to neonatal/ infant infection, deaths, disability, stillbirths and maternal infection.
The World Health Organization (WHO) identified the development of GBS vaccines suitable for maternal immunization in pregnancy and use in low- and middle-income countries (LMICs) as a priority in 2015.
The WHO Full value of vaccines assessment of Group B streptococcus vaccines published on 3 November 2021 describes the global public health rationale for developing vaccines against disease caused by GBS for maternal immunization, to inform decision making across the continuum of vaccine development and uptake with a line of sight to sustainable public health impact.
Main report
Group B Streptococcus vaccine: full value vaccine assessment
Group B streptococcus (GBS) is an important cause of disease burden in every region worldwide, contributing to neonatal/infant infection, deaths, disability,...
Group B streptococcus (GBS) is an important cause of disease burden in every region worldwide, contributing to neonatal/ infant infection, deaths, disability,...
Technical reports
Full value of vaccine assessment: Group B streptococcus vaccine – Policy and implementation issues
Maternal immunization can play an important role in improving maternal, fetal and neonatal health and has the potential to be an important tool in the...
This report describes the potential financial outcomes that can be expected from successful development of a Group B streptococcus (GBS) vaccine that...
Additional resources